NZ274713A - Pharmaceutical compositions comprising ranitidine and calcium carbonate - Google Patents
Pharmaceutical compositions comprising ranitidine and calcium carbonateInfo
- Publication number
- NZ274713A NZ274713A NZ274713A NZ27471394A NZ274713A NZ 274713 A NZ274713 A NZ 274713A NZ 274713 A NZ274713 A NZ 274713A NZ 27471394 A NZ27471394 A NZ 27471394A NZ 274713 A NZ274713 A NZ 274713A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pharmaceutical composition
- ranitidine
- calcium carbonate
- amount
- unit dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
New Zealand Paient Spedficaiion for Paient Number £74713
*
New Zealand No. 274713 International No.
TO BE ENTERED AFTER ACCEPTANCE AND PUBLICATION
Priority dates: 30.09.1993;
Complete Specification Filed: 29.09.1994
Classification:^) A61K33/10; A61K31/34
Publication date: 24 October 1997
Journal No.: 1421
Title of Invention:
Ranitidine and calcium carbonate pharmaceutical combination product
Name, address and nationality of applicant(s) as in international application form:
GLAXO WELLCOME INC., Five Moore Drive, Research Triangle Park, North Carolina 27709, United States of America
NO
NEW ZEALAND PATENTS ACT 1953
COMPLETE SPECIFICATION
New Zealand No. 274713 International No. PCT/US94/11132
NEW ZEALAND PATENTS ACT 1953 COMPLETE SPECIFICATION
Title of Invention:
Ranitidine and calcium carbonate pharmaceutical combination product
Name, address and nationality of applicant(s) as in international application form:
GLAXO WELLCOME INC, of Five Moore Drive, Research Triangle Park, North Carolina 27709, United States of America. Gov-iyxaz-vj *
1-CdlWoeA Wy
WO 95/08997 PCT/US94/11132
274713
RANITIDINE AND CALCIUM CARBONATE PHARMACEUTICAL COMBINATION PRODUCT BACKGROUND OF THE INVENTION
Ranitidine, chemically identified as N-[2-[[[5-(dimethylamino)methyl-2-furany]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine (see U.S. Patents 4,128,658; 4,521,431; 4,585,790 and 4,672,133 incorporated herein by reference), is an antagonist to histamine H2 receptors. As used herein the term "ranitidine" refers to the free base and the pharmaceutical^ acceptable acid addition salts thereof unless otherwise noted. This drug is widely used in the treatment of duodenal ulcers in humans in the form of the hydrochloride salt. While the drug is generally given orally or by injection, the oral route is preferred. Ranitidine HCI is sold under the trademark Zantac® by Glaxo Inc. of Research Triangle Park, North Carolina.
Calcium carbonate is used as an antacid for fast relief of acid indigestion, heartburn, sour stomach and upset stomach associated with those symptoms. It is used in antacids sold commercially under the trademark Turns® by SmithKline Beecham Consumer Brands of Pittsburgh, Pennsylvania and is a buffer in Ascriptin® analgesic in combination with aspirin, magnesium hydroxide and aluminum hydroxide as sold by Rorer Consumer Pharmaceuticals of Fort Washington.^Pennsylvania. U.S. Patent 4,650,669 to Alexander describes formulations for pharmaceuticals containing calcium carbonate.
Pharmaceuticals having both ranitidine or another H2 receptor antagonist and NaHC03 include the effervescent compositions described by Schaeffer in U.S. Patent 5,102,665. An effervescent pharmaceutical comprising an antacid effervescent couple, an antacid and an histamine ^-antagonist is described in US Patent 4,824, 664 issued to Tarral. Other disclosures of combinations H2-antagonists and antacids are found in European Patent Specification No. 286,781.
PCT Publication WO/92/00102 published 9 January 1992 to Davis describes coadministration of a histamine H2-receptor antagonist and antacid for the treatment of gastric disorder, e.g., Example 17 thereof listing calcium carbonate.
WO 95/08997 PCT/DS94/11132
r~
■ \ f \ - -2-
PCT Publication WO 93/12779 published 8 July 1993 to Davis describes coadministration of a histamine H2-receptor antagonist and antacid for the treatment of gastric disorder, e.g., Example 14 thereof listing calcium carbonate.
US Patent 5,229,137 issued to Wolfe describes the co-administration of a histamine H^receptor antagonist and an antacid for the treatment of episodic heartburn, e.g., Example IV thereof relating to the co-administration of ranitidine and Turns® tablets.
SUMMARY OF THE INVENTION
Pharmaceutical compositions such as tablets containing both calcium carbonate and ranitidine. The composition provides relief from many gastrointestinal diseases and symptoms.
DETAILED DESCRIPTION OF THE INVENTION
The composition of the invention is substantially free of acid, e.g., acid as may be used as part of an acid-base couple to produce effervescence.
Ranitidine
Preferably, the ranitidine is used in the present invention as its hydrochloride and in the Form 2 crystalline form.
Calcium Carbonate
Calcium carbonate, also known as carbonic acid calcium salt, occurs in nature as the minerals aragonite, calcite and vaterite. In the present invention, the 30 calcium carbonate may be used in the calcite form and be essentially free of the aragonite crystal form.
The calcium carbonate employed in the present invention can be in the particulate form. Suitable particulate calcium carbonate is Albaglos®, supplied by Pfizer, at its facility in Adams, Massachusetts. Albaglos is a precipitated calcium carbonate made by starting with high quality CaC03 and burning it to create CO2 and CaO (lime). The CaO is dissolved in H2O to create a milk of lime solution (CaCOH/2). The CO2 (which was previously captured) is injected into the solution, causing pure crystals of CaC03 to precipitate.
Other Ingredients
Other known pharmaceutical excipients such as flavorings, taste masking agents, lubricants, surfactants, binders or coloring agents and the like may be optionally added into the tablet composition of the present invention. Typical flavorings include grapefruit, lemon, mint and orange, and/or sweeteners such as aspartame or sodium saccharin. A small amount of diocMsodium sulfosuccinate (DOSS also known as docusate sodium) solution, for instance, n\-y be added as a surfactant, and/or a small amount of fumaric acid may be added as a lubricant. These excipients are usually added in the amount of 0.001% to 100% weight/weight, more particularly 0.01% to 60% weight/weight, of the CaC03.
Taste-masking ingredients and formulation techniques known in the art may be applied in the pharmaceutical composition of the invention. Examples include those in UK Patent Specification Nos 2198352 (liquid preparations), 2219940 (effervescent tablets), 2218333 (ranitidine resinate), 2218336 (film-coated tablets), 2229094 (gelatin capsules), 2262445 (pulsed-release formulation), European Patent Specification Nos 349103, 459695, 473431, 523847 and 538034 (chewable tablets), 542364 (controlled-release formulations), International Patent Specification Nos W092/21328 (chewable compositions), W094/08560 (chewable tablets), W094/05260 (aqueous compositions), W094/08576 (lipid-coated granules), Canadian Patent Specification No. 2068366 (taste-masked powder), United States Patent Specification Nos 5169864 and 5304571 (aqueous compositions) which patent specifications are incorporated herein by reference.
Suitable binders for use in tablet preparation include methylcellulose, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, alginic acid, ethylcellulose, acacia, gelatin, pregelatinized starch, sucrose syrup,
polyvinylpyrrolidone and guar gum. A particular binder is polyvinylpyrrolidone (povidone).
Suitable lubricants for use in tablet preparation include magnesium stearate, zinc stearate, calcium stearate, stearic acid, sodium stearyl fumerate, hydrogenated vegetable oils, glyceryl palmitosterate, glyceryl behenate, sodium benzoate, sodium lauryl sulphate, magnesium lauryl sulphate, mineral oil, talc and mixtures thereof. Magnesium stearate is a particular lubricant.
Suitable dessicants for use in tablet preparation include silica gel.
Dose
Ranitidine may be used in the composition of the present invention in an amount of 25 to less than 100 mg per dose, e.g., about 30 to 90 mg calculated as ranitidine base. In particular, a dose of about 50 to 80 mg, e.g., 75 mg may be used.
Calcium carbonate may be used in the unit dose composition of the present invention in an amount of about 250 mg to 1000 mg to provide an antacid neutralizing capacity of about 5 to 40 mEq. A particular dose is about 500 mg of calcium carbonate.
The unit dose may be administered up to, for example, 6 times a day depending upon the unit dose used, the nature and severity of the conditions being treated, and the age and weight of the patient. Thus, for example, in the treatment of minor conditions where there is an advantage in lowering gastric acidity such as, for example, acid indigestion, over-indulgence of food or drink, acid stomach, sour stomach, waterbrash/regurgitation, heartburn, such as episodic heartburn, nocturnal heartburn, and meal-induced heartburn, gastritis and dyspepsia, lower and more frequent doses of ranitidine may be used, for example doses in the range of 25-95 mg, e.g., 40-75 mg ranitidine expressed as the weight of free base, such as 83.7 mg ranitidine hydrochloride, administered up to 6 times a day as and when required.
G1071
27 4 7 1 3
It will be appreciated that reference to treatment is intended to include prophylaxis as well as the alleviation of established symptoms.
Pharmaceutical Presentation
The pharmaceutical composition of the invention may be in the form of a solid particulate, e.g., a powder, with the 2 ingredients present homogeneously so that the unit dose would be a measure such as a teaspoonful. Alternatively, the composition can be used in the form of a liquid where the unit dose would be a 10 liquid measure, e.g., 10 ml. Most conveniently, the composition of the invention is used as a pre-formed unit dose such as a tablet, bMayer tablet with separate location for the "ranitidine and the calcium carbonate, capsule or other particular modification such as a gelcap, caplet, tongue tablet or chewable tablet.
Tabletina
To produce tablets of the composition according to the present invention, the active ingredients and excipients may be subject to dry slugging, wet granulation or dry blending followed by ^compression into * tablets using an appropriate tablet press fitted with suitable punches.
Capsules
To produce capsules of the composition according to the present invention, the 25 active ingredients and inactive excipients are mixed and filled into gelatin capsules as is conventional in the art
In a further aspect, the present invention provides the use of ranitidine, in an amount of 25 to less than lOOmg per dose, and calcium carbonate, in the preparation of a
pharmaceutical composition substantially free of acid, and for use in the treatment of episodic heartburn, nocturnal heartburn, meal-induced heartburn, gastritis, dyspepsia or gastrointestinal symptoms associated with the overindulgence of fcod and drink.
In yet another aspect, the present invention provides the use of ranitidine,
in an amount of 25 to less than 100 mg per dose and calcium carbonate, in the preparation of a pharmaceutical composition substantially free of acid and for use in the treatment and prevention of duodenalylcers^-pathologieai-^roer-secretary conditions, gastric ulcers, gastro-e^c^fcia^i'/refiux or esqphagitis.
2 2 JUL 1S3?
RECEIVED
WO 95/08997 PCT/US94/11132
Example 1
The following ingredients are mixed and formulated into tablets in a conventional manner.
ranitidine hydrochloride 83.7 grams calcium carbonate 500 grams starch 80 grams powdered lactose 80 grams talc 20 grams
763.7 grams
The above ingredients ars combined, mixed and than compressed into slugs. The slugs may then be ground to form granules that will pass through a 14 to 16 mesh screen. The granules may then be recompressed into tablets using a suitable compression mold to form 1000 tablets, each weighing about 763.7 mg.
Example 2
The following is a bi-layer tablet to cover any incompatibilities between the ingredients.
Ranitidine Layer mg/tablet
Ranitidine hydrochloride 84.0
Microcrystalline cellulose USP 64.5
Magnesium stearate USNF 1.5
The ranitidine hydrochloride (taste-masked if required) is blended with the microcrystalline cellulose and magnesium stearate.
Antacid Layer mg/tablet
Calcium carbonate precipitated USP 500.0
Sucrose 346.0
Flavor/sweetener qs
Magnesium stearate USNF 4.0
Claims (16)
1. A pharmaceutical composition comprising ranitidine in an amount of 25 to less than 100 mg per dose and calcium carbonate, wherein the ccnposition is substantially free of acid.
2. The pharmaceutical composition of Claim 1, wherein said ranitidine is in the 10 form of ranitidine hydrochloride salt.
3. The pharmaceutical composition of Claim 1, wherein said ranitidine is present in an amount of about 30 to 90 mg, calculated as ranitidine free base, per unit dose of said pharmaceutical composition. 15
4. The pharmaceutical composition of Claim 1, wherein said ranitidine is present in an amount of 25 or 75 mg, calculated as ranitidine free base, per unit dose of said pharmaceutical composition. 20
5. The pharmaceutical composition of Claim 1, wherein said calcium carbonate is present in an amount of about 250 to 1000 mg per unit dose of said pharmaceutical composition.
6. The pharmaceutical composition of Claim 1, in the form of a solid particulate.
7. The pharmaceutical composition of Claim 1, in the form of a liquid.
8. The pharmaceutical composition of Claim 1, in the form of a solid unit dose. 30 9. The pharmaceutical composition of Claim 8, wherein said solid unit dose is a tablet or capsule. io. The pharmaceutical composition of Claim 1, further comprising one or more flavoring agents, taste masking agents, binders, lubricants, surfactants or 35 coloring agents.
9. H Z PATENT office. on »<'! ^^7
10. G1071 274 7 1 3 -9-
11. The pharmaceutical composition of Claim 1, in the form of a bi-layer tablet.
12. The pharmaceutical composition of Claim 1, wherein said composition 5 contains only said ranitidine and calcium carbonate as active ingredients.
13. The use of ranitidine, in an amount of 25 to less than 100 mg per dose, and calcium carbonate, in the preparation of a pharmaceutical composition substantially free of acid and for use in the treatment of episodic heartburn, nocturnal heartburn, meal-induced heartburn, gastritis, dyspepsia or gastro- 10 intestinal symptoms associated with the overindulgence of food and drink.
14. the use of ranitidine, in an amount of 25 to less than 100 mg per dose, and calcium carbonate, in the preparation of a pharmaceutical composition substantially free of acid and for use in the treatment and prevention of 15 duodenal ulcers, pathological hypersecretary conditions, gastric ulcers; gastro-esophageai reflux or erosive esophagitis.
15. A pharmaceutical composition as defined in claim 1 substantially as herein described with reference to any example thereof.
16. The use according to claim 13 or claim 14 substantially as herein described with reference to any example thereof. END OF CLAIMS N.Z. PATENT OKvCi-: J r- .'* r<*?
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12951793A | 1993-09-30 | 1993-09-30 | |
PCT/US1994/011132 WO1995008997A1 (en) | 1993-09-30 | 1994-09-29 | Ranitidine and calcium carbonate pharmaceutical combination product |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ274713A true NZ274713A (en) | 1997-10-24 |
Family
ID=22440376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ274713A NZ274713A (en) | 1993-09-30 | 1994-09-29 | Pharmaceutical compositions comprising ranitidine and calcium carbonate |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0721338A1 (en) |
JP (1) | JPH09503212A (en) |
CN (1) | CN1140996A (en) |
AU (1) | AU677108B2 (en) |
BG (1) | BG100456A (en) |
CA (1) | CA2168846A1 (en) |
CZ (1) | CZ76996A3 (en) |
HU (1) | HUT75061A (en) |
IL (1) | IL111094A0 (en) |
NO (1) | NO961297L (en) |
NZ (1) | NZ274713A (en) |
OA (1) | OA10717A (en) |
PL (1) | PL316855A1 (en) |
SG (1) | SG44715A1 (en) |
SK (1) | SK40596A3 (en) |
WO (1) | WO1995008997A1 (en) |
ZA (1) | ZA947553B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5560701B2 (en) * | 2008-12-26 | 2014-07-30 | ライオン株式会社 | Ranitidine-containing pharmaceutical solid preparation and method for producing ranitidine-carrying particles |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2222772B (en) * | 1988-09-20 | 1992-05-13 | Glaxo Group Ltd | Pharmaceutical compositions |
WO1992000102A1 (en) * | 1990-06-22 | 1992-01-09 | Beecham Group Plc | Novel treatment |
GB9127150D0 (en) * | 1991-12-20 | 1992-02-19 | Smithkline Beecham Plc | Novel treatment |
US5229137A (en) * | 1992-05-06 | 1993-07-20 | Brigham And Women's Hospital, Inc. | Methods and pharmaceutical compositions for treating episodic heartburn |
-
1994
- 1994-09-28 ZA ZA947553A patent/ZA947553B/en unknown
- 1994-09-29 AU AU79253/94A patent/AU677108B2/en not_active Ceased
- 1994-09-29 SG SG1996006196A patent/SG44715A1/en unknown
- 1994-09-29 EP EP94929984A patent/EP0721338A1/en not_active Withdrawn
- 1994-09-29 SK SK405-96A patent/SK40596A3/en unknown
- 1994-09-29 JP JP7510481A patent/JPH09503212A/en active Pending
- 1994-09-29 WO PCT/US1994/011132 patent/WO1995008997A1/en not_active Application Discontinuation
- 1994-09-29 NZ NZ274713A patent/NZ274713A/en unknown
- 1994-09-29 IL IL11109494A patent/IL111094A0/en unknown
- 1994-09-29 CA CA002168846A patent/CA2168846A1/en not_active Abandoned
- 1994-09-29 HU HU9600810A patent/HUT75061A/en unknown
- 1994-09-29 CZ CZ96769A patent/CZ76996A3/en unknown
- 1994-09-29 PL PL94316855A patent/PL316855A1/en unknown
- 1994-09-29 CN CN94193540A patent/CN1140996A/en active Pending
-
1996
- 1996-03-08 OA OA60792A patent/OA10717A/en unknown
- 1996-03-27 BG BG100456A patent/BG100456A/en unknown
- 1996-03-29 NO NO961297A patent/NO961297L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
SK40596A3 (en) | 1997-02-05 |
NO961297D0 (en) | 1996-03-29 |
AU677108B2 (en) | 1997-04-10 |
CA2168846A1 (en) | 1995-04-06 |
NO961297L (en) | 1996-03-29 |
SG44715A1 (en) | 1997-12-19 |
CZ76996A3 (en) | 1996-10-16 |
IL111094A0 (en) | 1994-11-28 |
CN1140996A (en) | 1997-01-22 |
AU7925394A (en) | 1995-04-18 |
EP0721338A1 (en) | 1996-07-17 |
JPH09503212A (en) | 1997-03-31 |
ZA947553B (en) | 1995-05-26 |
PL316855A1 (en) | 1997-02-17 |
BG100456A (en) | 1996-11-29 |
HUT75061A (en) | 1997-03-28 |
HU9600810D0 (en) | 1996-05-28 |
OA10717A (en) | 2002-12-09 |
WO1995008997A1 (en) | 1995-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0664697B1 (en) | Ranitidine chewable tablets | |
US6645988B2 (en) | Substituted benzimidazole dosage forms and method of using same | |
US5989588A (en) | Methods and compositions for preventing and treating heartburn | |
AU2002330863A1 (en) | Novel substituted benzimidazole dosage forms and method of using same | |
EP0492247A1 (en) | Effervescent H2 blocker formulation | |
AU677108B2 (en) | Ranitidine and calcium carbonate pharmaceutical combination product | |
JP3587869B2 (en) | Pharmaceutical composition | |
CA2267503C (en) | Methods and compositions for preventing and treating heartburn | |
WO1996008238A1 (en) | Use of paracellular absorption enhancers such as glucose for enhaincing the absorption of histamine h2-antagonists | |
AU690664B2 (en) | Low dosage ranitidine compositions for the treatment of minor gastrointestinal disorders associated with excess acid secretion | |
PT1019066E (en) | Methods and compositions for preventing and treating heartburn | |
WO1996002262A2 (en) | Pharmaceutical compositions for the treatment of gastrointestinal distress comprising h2 receptor antagonists and antacids | |
MXPA96004553A (en) | Compositions of dosing ranitidine b |